Antipsychotic drugs are overused in Australia as a first-line response to managing behavioral and psychological symptoms experienced by people with dementia, particularly in residential aged care,” said Glenn Rees, Alzheimer’s Australia chief executive, in response to a report on ABC Lateline last week.
There are almost 280,000 Australians currently living with dementia, says the dementia charity. Without a significant medical breakthrough, that is expected to soar to almost 1 million by 2050.
The excessive use of antipsychotics for dementia patients in the UK has previously been criticized. However, interestinlgy, just last month a report from the Health and Social Care Information Centre (HSCIC) noted that the percentage of dementia patients in England being prescribed antipsychotic drugs fell sharply over the last six years (The Pharma Letter July 16). The first ever national primary care audit on the subject shows the percentage of dementia patients being prescribed antipsychotic drugs fell by 10 percentage points in the last six years – from 17% in 2006 to 7% in 2011.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze